All In Biotech

Drug Trial Radar · NCT07904845

A Study of BON-C1393 in Adults With Advanced Solid Tumors

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BON-C1393 in Patients With Selected Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Nov 23, 2026

Primary completion

Feb 27, 2029

Study completion Feb 27, 2029

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BON-C1393 monotherapy or in combination with other anticancer regimens in adults with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Dose Exploration) and Phase 1b (Dose Expansion).

Conditions

  • Solid Tumors
  • Advanced Solid Tumors

Interventions

  • BON-C1393Drug

    Administered intravenously

  • BevacizumabDrug

    Administered intravenously

  • CapecitabineDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Approximately 1 month
  2. Phase 1a: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)Time frame: Up to approximately 9 months
  3. Phase 1b: Overall Response Rate (ORR) Assessed by the InvestigatorTime frame: Up to approximately 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.